Trials / Not Yet Recruiting
Not Yet RecruitingNCT06814548
Immune Checkpoint Inhibitors (ICIs) Retreatment in Second-line Treatment of Advanced Gastric Cancer: a Retrospective, Real-world Study
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Yongxu Jia · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, retrospective, observational, real-world study. We collected general and clinical data of patients with advanced gastric cancer who were admitted to the First Affiliated Hospital of Zhengzhou University from January 2018 to July 2024.
Detailed description
All patients received combination therapy with ICIs inhibitors for at least 2 cycles in the first-line and at least 2 cycles of ICI inhibitor-based therapy in the second-line after first-line progression. The efficacy and safety of treatment were evaluated, including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), Pattern of immune progression after cross-line therapy, grade 3-5 treatment-related adverse events (TRAEs), and immune-related adverse events (irAEs). Cox regression model was used to investigate the influence of multiple factors on survival.
Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer
- Immune Checkpoint Inhibitors (ICIs)
- Second-line
- Retreatment
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | ICIs(Immune checkpoint inhibitors) | N |
Timeline
- Start date
- 2025-02-10
- Primary completion
- 2025-05-31
- Completion
- 2025-05-31
- First posted
- 2025-02-07
- Last updated
- 2025-02-07
Source: ClinicalTrials.gov record NCT06814548. Inclusion in this directory is not an endorsement.